Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in ...

From drug trials to mechanistic insights, EULAR 2025 delivers wide-ranging data that may inform tomorrow’s standards in ...

The safety update for Vyvgart rattled argenx’s shares on Monday, a reaction that analysts at William Blair said was “overdone ...

Medscape UK -- with comprehensive coverage of the NHS, UK & NICE guidelines, drugs alerts, and the latest medical research of interest to doctors in England, Scotland, Wales, and Northern Ireland.

Medscape News UK Sepsis Diagnosis Delays Pose Urgent Safety Risk: HSSIB Delayed sepsis diagnosis remains a persistent risk in the NHS, with the health safety watchdog urging reforms to improve ...

New Data at EULAR Signal Advances in RA, Myopathy, Gout From drug trials to mechanistic insights, EULAR 2025 delivers wide-ranging data that may inform tomorrow’s standards in rheumatology care.

Acetazolamide-related hypophosphatemia leading to cardiac arrest is extremely rare. Herein we report a 78-year-old female glaucoma patient who developed general weakness and acute respiratory ...

New Data at EULAR Signal Advances in RA, Myopathy, Gout From drug trials to mechanistic insights, EULAR 2025 delivers wide-ranging data that may inform tomorrow’s standards in rheumatology care.

EULAR 2025 Efgartigimod Use Extends to Myositis, Sjögren Disease Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in addition ...

Abstract Cardiovascular disease has been implicated as an important contributor to dementia. In the Baltimore Longitudinal Study of Aging cohort, for example, atherosclerosis of the intracranial ...